Information Provided By: 
Fly News Breaks for April 10, 2018
KPTI
Apr 10, 2018 | 07:01 EDT
JPMorgan analyst Eric Joseph added Karyopharm Therapeutics to his firm's Analyst Focus List and raised his price target for the shares to $20 from $19. The analyst views the stock's risk/reward as favorable into the Phase 2b refractory multiple myeloma data anticipated later this month. He sees 50%-90% upside on favorable data and downside of 15%-20% on mixed results. Joseph sees the potential for sustained Karyopharm share momentum post STORM data. He keeps an Overweight rating on the name.
News For KPTI From the Last 2 Days
There are no results for your query KPTI
